Literature DB >> 15447695

The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs.

Leslie Kelman1.   

Abstract

OBJECTIVES: This study of premonitory symptoms in migraine was performed to document the frequency, duration, and types of symptoms in a large group of migraine patients.
BACKGROUND: Prodrome importance continues to be debated. Intervention early in the migraine attack is assuming more importance and necessitates better knowledge of the prodrome.
METHODS: A total of 893 migraine patients (IHS 1.1-1.7) were evaluated at first visit. Prodrome frequency, duration, and characteristics were analyzed in the total migraine population IHS 1.1-1.7 and IHS 1.1-1.6 migraine.
RESULTS: A total of 32.9% of IHS migraine 1.1-1.6 patients reported prodrome symptoms with an average of 9.42 hours. IHS 1.1-1.7 migraine reported 29.7% and 6.8 hours, respectively. The most commonest symptoms were tiredness, mood change, and gastrointestinal symptoms; all three of these symptoms were present together in 17% of the patients with prodrome. The duration of prodrome was less than 1 hour in 45.1%, 1-2 hours in 13.6%, 2-4 hours in 15.0%, 4-12 hours in 13.1%, and greater than 12 hours in 13.2%. IHS 1.1-1.7 patients showed similar findings. IHS 1.1-1.6 patients with prodrome differed from patients without prodrome in having more triggers as a whole (P <.01), more individual triggers including alcohol (P <.01), hormones (P <.01), light (P <.001), not eating (P <.05), perfume (P <.01), stress (P <.01), and weather changes (P <.05), a longer duration of aura (P <.05), longer time between aura and headache (P <.05), more aura with no headache (P <.05), longer time to peak of headache (P <.05), longer time to respond to triptan (P <.05), longer maximum duration of headache (P <.05), and more headache associated nausea (P <.05), more headache associated running of the nose or tearing of the eyes (P <.05), more postdrome syndrome (P <.05), and longer duration of postdrome syndrome (P <.001).
CONCLUSIONS: This study provides a portrait of prodrome in a large cohort of patients. It highlights differences between patients with prodrome and patients not having prodrome, and it draws attention to the potential of preventing the headache phase of the acute migraine attack.

Entities:  

Mesh:

Year:  2004        PMID: 15447695     DOI: 10.1111/j.1526-4610.2004.04168.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  46 in total

1.  Use of dopamine antagonists in treatment of migraine.

Authors:  Michael J Marmura
Journal:  Curr Treat Options Neurol       Date:  2012-02       Impact factor: 3.598

2.  Hypothalamic regulation of headache and migraine.

Authors:  Arne May; Rami Burstein
Journal:  Cephalalgia       Date:  2019-08-29       Impact factor: 6.292

Review 3.  Migraine: multiple processes, complex pathophysiology.

Authors:  Rami Burstein; Rodrigo Noseda; David Borsook
Journal:  J Neurosci       Date:  2015-04-29       Impact factor: 6.167

4.  The sinus headache explained.

Authors:  Murugan Ravindran; James N Baraniuk
Journal:  Curr Allergy Asthma Rep       Date:  2010-05       Impact factor: 4.806

5.  Visual Field Losses in Patients with Migraine without Aura and Tension-Type Headache.

Authors:  Arif Ü Yener; Osman Korucu
Journal:  Neuroophthalmology       Date:  2017-01-11

Review 6.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 7.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

Review 8.  Cerebral hemodynamics in the different phases of migraine and cluster headache.

Authors:  Jakob M Hansen; Christoph J Schankin
Journal:  J Cereb Blood Flow Metab       Date:  2017-08-31       Impact factor: 6.200

9.  Survey of migraine sufferers with dogs to evaluate for canine migraine-alerting behaviors.

Authors:  Dawn A Marcus; Amrita Bhowmick
Journal:  J Altern Complement Med       Date:  2012-12-04       Impact factor: 2.579

Review 10.  Migraine pathogenesis and state of pharmacological treatment options.

Authors:  Till Sprenger; Peter J Goadsby
Journal:  BMC Med       Date:  2009-11-16       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.